Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamine. 1977

E J Hall, and M Astor, and C Geard, and J Biaglow

The selective cytotoxicity which Ro-07-0582 exhibits towards hypoxic cells is strongly temperature-dependent. This cytotoxicity is reduced by the radical scavenger cysteamine, suggesting that nitro radicals or nitroso intermediates are involved in cell killing by the drug. Chromosome aberrations are not induced by Ro-07-0582 even when the surviving fraction is reduced to 0-01.

UI MeSH Term Description Entries
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D005720 Gamma Rays Penetrating, high-energy electromagnetic radiation emitted from atomic nuclei during NUCLEAR DECAY. The range of wavelengths of emitted radiation is between 0.1 - 100 pm which overlaps the shorter, more energetic hard X-RAYS wavelengths. The distinction between gamma rays and X-rays is based on their radiation source. Gamma Wave,Gamma Radiation,Nuclear X-Rays,Radiation, Gamma,X-Rays, Nuclear,Gamma Radiations,Gamma Ray,Gamma Waves,Nuclear X Rays,Nuclear X-Ray,Ray, Gamma,Wave, Gamma,Waves, Gamma,X Rays, Nuclear,X-Ray, Nuclear
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

E J Hall, and M Astor, and C Geard, and J Biaglow
March 1981, British journal of cancer,
E J Hall, and M Astor, and C Geard, and J Biaglow
March 1977, British journal of cancer,
E J Hall, and M Astor, and C Geard, and J Biaglow
January 1977, International journal of radiation oncology, biology, physics,
E J Hall, and M Astor, and C Geard, and J Biaglow
March 1977, British journal of cancer,
E J Hall, and M Astor, and C Geard, and J Biaglow
April 1979, British journal of cancer,
E J Hall, and M Astor, and C Geard, and J Biaglow
March 1977, Radiation research,
E J Hall, and M Astor, and C Geard, and J Biaglow
January 1977, International journal of radiation oncology, biology, physics,
E J Hall, and M Astor, and C Geard, and J Biaglow
March 1977, British journal of cancer,
E J Hall, and M Astor, and C Geard, and J Biaglow
December 1977, Strahlentherapie,
E J Hall, and M Astor, and C Geard, and J Biaglow
June 1976, The British journal of radiology,
Copied contents to your clipboard!